💡 Board approved a share buyback of up to 2.23% of equity at ₹1,000 per share, signaling confidence and returning capital to shareholders.
What Happened
The Board of Directors of Windlas Biotech Limited, in its meeting held on April 17, 2026, has approved a proposal to buy back up to 4,70,000 fully paid-up equity shares of the company. This represents 2.23% of the total equity share capital. The buyback will be executed at a price of ₹1,000 per equity share, for an aggregate amount not exceeding ₹47 crore.
Key Details
- Company: Windlas Biotech Limited
- Event Type: Other
- Filing Date: 17-Apr-2026 14:32:13
- NSE Filing: View Document
Why It Matters
A share buyback is often interpreted as a signal of management's confidence in the company's future prospects and financial health. By returning capital to shareholders, the company indicates that it believes its shares are undervalued and that this is a prudent use of surplus cash. The buyback is proposed to be made from all shareholders excluding promoters and members of the promoter group, with a specific reservation for small shareholders as per SEBI regulations. The record date to determine shareholder eligibility has been fixed as April 24, 2026.
Disclaimer: This is publicly available information sourced from NSE. Not investment advice.
Get signals like this instantly
Free Telegram alerts within 2 minutes of NSE filing
Join SuperStock Free